INTRODUCTION {#s1}
============

Since radiotherapy for prostate cancer is a standard treatment option for localized prostate cancer, its toxicity should be clearly addressed. In a previous survey study conducted from 1995 to 2006 in Osaka, Japan, which was intended to clarify time trends in radiotherapy and its biochemical relapse-free survival (bRFS) outcomes, we made the interesting discovery that 87% of patients had been treated with a highly uniform mode of radiotherapy, that is, with classical 4-field 70 Gy in 35 fractions \[[@RRS083C1]\]. While that study was being conducted, CT simulation was introduced and developed, and almost all institutions had replaced 2D simulation with 3D simulation by 2006. This resulted in a reduction in the size of the portal field. We realized that we could obtain very pure data for an investigation of the relationship between portal field size and late toxicity rate, especially for rectal bleeding, in view of the uniform setting of dose-fractionation and beam arrangement. The findings of this investigation are the main subject of this article. Dearnaley *et al*. had already conducted a prospective randomized trial comparing 1.0 and 1.5 cm margins, and concluded that a larger margin was associated with significantly higher incidence of toxicities \[[@RRS083C2]\]. However, their study included only 126 patients, who had been assigned to 2 × 2 arms (64 Gy and 74 Gy groups, and 1.0 and 1.5 cm margin groups). Moreover, their treatment planning included two phases comprising a 3-field phase and a 6-field phase. We aimed to repeat the investigation with a larger Japanese patient cohort, treated with more uniform dose-fractionation and beam arrangement, although in a retrospective manner.

MATERIALS AND METHODS {#s2}
=====================

A brief summary of the previous survey study {#s2a}
--------------------------------------------

In our previous study \[[@RRS083C1]\], data were collected for 652 consecutive patients with clinically localized prostate cancer (T1-4N0M0), who had been treated with definitive external beam radiotherapy (EBRT) of 60 Gy or more at one of the 11 participating institutions, mainly in Osaka, Japan, from 1995 through 2006. Of the 652 patients, 436 met the enrolment criteria and were analysed. The main findings were: (i) the number of radiotherapy patients showed a 10-fold increase over 10 years; (ii) the dominant dose-fractionation was 70 Gy/35 fractions (87%); (iii) hormone therapy had been administered to 95% of the patients; (iv) the 3- and 5-year bRFS rates were 85% and 70%, respectively; (v) toxicity data was not available.

An interesting finding was that as many as 87% of the patients had received radiotherapy in a highly uniform manner, that is, with the classical 4-field technique using a dose-fractionation schedule of 70 Gy/35 fractions. We therefore planned the second survey by focusing on detailed late toxicity data and irradiation field data obtained with a uniform setting of 4-field 70 Gy/35 fractions.

Data collection {#s2b}
---------------

Five institutions participated in the present study. Data collected for the 362 patients who are the subject of this study are described in the Results section.

All the data were collected by physicians (radiation oncologists or urologists), who are also the authors of this paper, and no non-physician surveyors took any part in this study. Detailed information was collected about portal field size and other parameters of radiotherapy. Late toxicity grading was performed by retrospectively reviewing medical charts, strictly according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The concrete description of each relevant CTCAE Term was gathered as Tables [1](#RRS083TB1){ref-type="table"} and [2](#RRS083TB2){ref-type="table"}, which had been distributed to the surveyors as references. All data were sent to Osaka University, analysed by the first author, and finally reviewed and approved by all the authors. Table 1.Late genitourinary toxicity scale extracted from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0Renal and urinary disordersGradeAdverse Event12345HematuriaAsymptomatic; clinical orSymptomatic; urinary catheterGross hematuria; transfusion, IVLife-threatening consequences;Deathdiagnostic observations only;or bladder irrigation indicated;medications or hospitalizationurgent radiologic or operativeintervention not indicatedlimiting instrumental ADLindicated; elective endoscopic,intervention indicatedradiologic or operativeintervention indicated; limitingself care ADLDefinition: A disorder characterized by laboratory test results that indicate blood in the urine.Urinary frequencyPresentLimiting instrumental ADL;------medical management indicatedDefinition: A disorder characterized by urination at short intervals.Urinary incontinenceOccasional (e.g. with coughing,Spontaneous; pads indicated;Intervention indicated (e.g.----sneezing, etc.), pads notlimiting instrumental ADLclamp, collagen injections);indicatedoperative intervention indicated;limiting self care ADLDefinition: A disorder characterized by inability to control the flow of urine from the bladder.Urinary retentionUrinary, suprapubic orPlacement of urinary,Elective operative or radiologicLife-threatening consequences;Deathintermittent catheter placementsuprapubic or intermittentintervention indicated;organ failure; urgent operativenot indicated; able to void withcatheter placement indicated;substantial loss of affectedintervention indicatedsome residualmedication indicatedkidney function or massDefinition: A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.Urinary tract obstructionAsymptomatic; clinical orSymptomatic but noSymptomatic and altered organLife-threatening consequences;Deathdiagnostic observations onlyhydronephrosis, sepsis or renalfunction (e.g. hydronephrosis,urgent intervention indicateddysfunction; urethral dilation,or renal dysfunction); electiveurinary or suprapubic catheterradiologic, endoscopic orindicatedoperative intervention indicatedDefinition: A disorder characterized by blockage of the normal flow of contents of the urinary tract.Urinary tract painMild painModerate pain; limitingSevere pain; limiting self care----instrumental ADLADLDefinition: A disorder characterized by a sensation of marked discomfort in the urinary tract.Urinary urgencyPresentLimiting instrumental ADL;------medical management indicatedDefinition: A disorder characterized by a sudden compelling urge to urinate.Urine discolorationPresent--------Definition: A disorder characterized by a change in the color of the urine.Renal and urinary disorders -Asymptomatic or mildModerate, local or noninvasiveSevere or medically significantLife-threatening consequences;DeathOther, specifysymptoms; clinical or diagnosticintervention indicated; limitingbut not immediately life-urgent intervention indicatedobservations only; interventioninstrumental ADLthreatening; hospitalization ornot indicatedprolongation of existinghospitalization indicated;disabling; limiting self care ADL Table 2.Late gastrointestinal toxicity scale extracted from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0Gastrointestinal disordersGradeAdverse Event12345Abdominal painMild painModerate pain; limitingSevere pain; limiting self care----instrumental ADLADLDefinition: A disorder characterized by a sensation of marked discomfort in the abdominal region.Anal fistulaAsymptomatic; clinical orSymptomatic; altered GISeverely altered GI function;Life-threatening consequences;Deathdiagnostic observations only;functiontube feeding, TPN orurgent intervention indicatedintervention not indicatedhospitalization indicated;elective operative interventionindicatedDefinition: A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.Anal hemorrhageMild; intervention not indicatedModerate symptoms; medicalTransfusion, radiologic,Life-threatening consequences;Deathintervention or minorendoscopic, or electiveurgent intervention indicatedcauterization indicatedoperative intervention indicatedDefinition: A disorder characterized by bleeding from the anal region.Anal mucositisAsymptomatic or mildSymptomatic; medicalSevere symptoms; limiting selfLife-threatening consequences;Deathsymptoms; intervention notintervention indicated; limitingcare ADLurgent intervention indicatedindicatedinstrumental ADLDefinition: A disorder characterized by inflammation of the mucous membrane of the anus.Anal necrosis----TPN or hospitalization indicated;Life-threatening consequences;Deathradiologic, endoscopic, orurgent operative interventionoperative intervention indicatedindicatedDefinition: A disorder characterized by necrotic process occurring in the anal region.Anal painMild painModerate pain; limitingSevere pain; limiting self care----instrumental ADLADLDefinition; A disorder characterized by a sensation of marked discomfort in the anal region.Anal stenosisAsymptomatic; clinical orSymptomatic; altered GISymptomatic and severelyLife-threatening consequences;Deathdiagnostic observations only;functionaltered GI function; non-urgent operative interventionintervention not indicatedemergent operative interventionindicatedindicated; TPN or hospitalizationindicatedDefinition: A disorder characterized by a narrowing of the lumen of the anal canal.Anal ulcerAsymptomatic; clinical orSymptomatic; altered GISeverely altered GI function;Life-threatening consequences;Deathdiagnostic observations only;functionTPN indicated; electiveurgent operative interventionintervention not indicatedoperative or endoscopicindicatedintervention indicated; disablingDefinition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the anal canal.ConstipationOccasional or intermittentPersistent symptoms withObstipation with manualLife-threatening consequences;Deathsymptoms; occasional use ofregular use of laxatives orevacuation indicated; limitingurgent intervention indicatedstool softeners, laxatives,enemas; limiting instrumentalself care ADLdietary modification, or enemaADLDefinition: A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.DiarrheaIncrease of \<4 stools per dayIncrease of 4-6 stools per dayIncrease of ≥7 stools per dayLife-threatening consequences;Deathover baseline; mild increase inover baseline; moderateover baseline; incontinence;urgent intervention indicatedostomy output compared toincrease in ostomy outputhospitalization indicated; severebaselinecompared to baselineincrease in ostomy outputcompared to baseline; limitingself care ADLDefinition: A disorder characterized by frequent and watery bowel movements.Fecal incontinenceOccasional use of pads requiredDaily use of pads requiredSevere symptoms; elective----operative intervention indicatedDefinition: A disorder characterized by inability to control the escape of stool from the rectum.Hemorrhoidal hemorrhageMild; intervention not indicatedModerate symptoms; medicalTransfusion, radiologic,Life-threatening consequences;Deathintervention or minorendoscopic, or electiveurgent intervention indicatedcauterization indicatedoperative intervention indicatedDefinition: A disorder characterized by bleeding from the hemorrhoids.HemorrhoidsAsymptomatic; clinical orSymptomatic; banding orSevere symptoms; radiologic,----diagnostic observations only;medical intervention indicatedendoscopic or elective operativeintervention not indicatedintervention indicatedDefinition: A disorder characterized by the presence of dilated veins in the rectum and surrounding area.Ileus--Symptomatic; altered GISeverely altered GI function;Life-threatening consequences;Deathfunction; bowel rest indicatedTPN indicatedurgent intervention indicatedDefinition: A disorder characterized by failure of the ileum to transport intestinal contents.ProctitisRectal discomfort, interventionSymptoms (e.g. rectalSevere symptoms; fecalLife-threatening consequences;Deathnot indicateddiscomfort, passing blood orurgency or stool incontinence;urgent intervention indicatedmucus); medical interventionlimiting self care ADLindicated; limiting instrumentalADLDefinition: A disorder characterized by inflammation of the rectum.Rectal fistulaAsymptomatic; clinical orSymptomatic; altered GISeverely altered GI function;Life-threatening consequences;Deathdiagnostic observations only;functionTPN or hospitalization indicated;urgent intervention indicatedintervention not indicatedelective operative interventionindicatedDefinition: A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.Rectal hemorrhageMild; intervention not indicatedModerate symptoms; medicalTransfusion, radiologic,Life-threatening consequences;Deathintervention or minorendoscopic or electiveurgent intervention indicatedcauterization indicatedoperative intervention indicatedDefinition: A disorder characterized by bleeding from the rectal wall and discharge from the anus.Rectal mucositisAsymptomatic or mildSymptomatic; medicalSevere symptoms; limiting selfLife-threatening consequences;Deathsymptoms; intervention notintervention indicated; limitingcare ADLurgent operative interventionindicatedinstrumental ADLindicatedDefinition: A disorder characterized by inflammation of the mucous membrane of the rectum.Rectal necrosis----Tube feeding or TPN indicated;Life-threatening consequences;Deathradiologic, endoscopic, orurgent operative interventionoperative intervention indicatedindicatedDefinition: A disorder characterized by a necrotic process occurring in the rectal wall.Rectal obstructionAsymptomatic; clinical orSymptomatic; altered GIHospitalization indicated;Life-threatening consequences;Deathdiagnostic observations only;function; limiting instrumentalelective operative interventionurgent operative interventionintervention not indicatedADLindicated; limiting self care ADL;indicateddisablingDefinition: A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.Rectal painMild painModerate pain; limitingSevere pain; limiting self care----instrumental ADLADLDefinition: A disorder characterized by a sensation of marked discomfort in the rectal region.Rectal perforation--Symptomatic; medicalSevere symptoms; electiveLife-threatening consequences;Deathintervention indicatedoperative intervention indicatedurgent operative interventionindicatedDefinition: A disorder characterized by a rupture in the rectal wall.Rectal stenosisAsymptomatic; clinical orSymptomatic; altered GISeverely altered GI function;Life-threatening consequences;Deathdiagnostic observations only;functiontube feeding or hospitalizationurgent operative interventionintervention not indicatedindicated; elective operativeindicatedintervention indicatedDefinition: A disorder characterized by a narrowing of the lumen of the rectum.Rectal ulcerAsymptomatic; clinical orSymptomatic; altered GISeverely altered GI function;Life-threatening consequences;Deathdiagnostic observations only;function (e.g. altered dietaryTPN indicated; electiveurgent operative interventionintervention not indicatedhabits, vomiting, diarrhea)operative or endoscopicindicatedintervention indicated; disablingDefinition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the rectum.Gastrointestinal disorders -Asymptomatic or mildModerate; minimal, local orSevere or medically significantLife-threatening consequences;DeathOther, specifysymptoms: clinical or diagnosticnoninvasive interventionbut not immediately life-urgent intervention indicatedobservations only; interventionindicated; limiting age-threatening; hospitalization ornot indicatedappropriate instrumental ADLprolongation of existinghospitalization indicated;disabling; limiting self care ADL

Statistical Analysis {#s2c}
--------------------

The unpaired *t* test was used to compare the averages of the two groups, while Fisher\'s exact test was used to compare the proportions. Kaplan-Meier curves were obtained for survival and toxicity rates, and the log-rank test was used to compare them. A *P*-value \<0.05 was deemed statistically significant. Statistical analysis was performed with PASW Statistics 18 software (SPSS, Inc., Chicago, IL, USA).

RESULTS {#s3}
=======

Data for a total of 362 patients, all of whom had been treated for T1-4N0M0 adenocarcinoma of the prostate between 1998 and 2006, were collected from five representative institutions in Osaka, Japan. Postoperative cases were not included. None of the patients had been irradiated to the elective lymph node region, and all had been treated with the classical 4-field technique using 70 Gy in 35 fractions with gantry angles of 0°, 90°, 180° and 270°.

The median and mean ages of the patients were both 70 years (range, 49--82). The median follow-up period was 4.5 years (range, 1.0--11.6), with a minimum of 1 year. The actuarial 5-year overall and prostate cancer-specific survival rates were 93% and 96%, respectively (Fig. [1](#RRS083F1){ref-type="fig"}). Fig. 1.(a) The 5-year overall survival rate was 93%. (b) The 5-year prostate cancer-specific survival rate was 96%.

Neoadjuvant hormone therapy had been administered to 328 patients (91%), 35 of whom (11 %) had been considered hormone-refractory at the time of radiotherapy. Adjuvant hormone therapy had been administered to 276 of the total of 362 patients (76%), and 179 of them (65%) had already discontinued the therapy at the time of this survey. The median durations of neoadjuvant and adjuvant hormone therapy were 8 months (range, 1--150) and 24 months (range, 1--129), respectively.

2D simulation was performed for 127 patients, all of whom had been treated between 1998 and 2003. The other 235 had been treated using 3D simulation with a CT-simulator between 1998 and 2006. Of the five institutions, three had a 1 cm-width multileaf collimator (MLC), one a 2-cm MLC and one a 1-cm MLC until 2006, which was then replaced with a 0.5-cm MLC. The energy of the anterior-posterior beam was 10 MV at four institutions, and 20 MV at one. The energy of the lateral beams was 10 MV at three institutions, and 18 MV and 20 MV at one each. A field-shrinking technique was used for almost all patients (357 of 362, or 99%), once for 340 (94%) and twice for the other 17 (5%). The first shrinking was performed at 60 Gy for 219 patients (61%), at 50 Gy for 76 (21%), at 40 Gy for 42 (12%), and at other doses for 20 patients (6%). The second shrinking was performed at 60 Gy for 12 patients (71%), at 66 Gy for 4 (24%), and at 50 Gy for 1 (6%).

For the original irradiation field, three institutions defined the clinical target volume (CTV) as the prostate plus the whole seminal vesicle (SV), and the other two institutions as the prostate plus a part of SV. As for the shrinking field, three institutions defined the CTV as the prostate plus a part of SV, and the other two as the prostate only. In the original field, the median margin (distance from the CTV to the block edge) was 1.5 cm (range, 1.5--3.0) except for in the posterior (rectal) direction, where it was 1.3 cm (range, 1.0--2.0). As for the shrinking field, the median margin was 1.3 cm (range, 1.0--2.0) except for in the posterior direction, where it was 0.8 cm (range, 0.6--1.5). In 2D simulation, a Foley catheter was placed and contrast medium was administered into the bladder and rectum for visualization, trying to keep the definition of CTV and field margin described as above as much as possible. Retrograde urethrography was not performed routinely.

The use of the CT-simulator significantly reduced the irradiation field size compared to that used for 2D simulation (Table [3](#RRS083TB3){ref-type="table"}). The mean ± standard deviation (SD) of the distance between block edges in the right--left (RL) direction was 10.8 ± 1.1 cm for 2D simulation compared to 8.4 ± 1.2 cm for 3D (CT) simulation (*P* \< 0.001). The corresponding values in the superior--inferior (SI) direction were 10.2 ± 1.0 cm and 8.2 ± 1.0 cm (*P* \< 0.001), and in the anterior--posterior (AP) direction 8.8 ± 0.9 cm and 7.7 ± 1.0 cm (*P* \< 0.001). Table 3.Comparison of 2D simulation and 3D (CT) simulation2D (*n* = 127)3D (*n* = 235)*P*Median follow--up period (range) (year)5.9 (1.1--11.6)4.0 (1.0--8.0)\<0.001Hormone therapy\<0.001 None1 (1%)30 (13%) Neoadjuvant only7 (6%)43 (18%) Adjuvant only1 (1%)1 (0%) Both neoadjuvant and adjuvant118 (93%)161 (69%)Multileaf collimator width\<0.001 0.5 cm0 (0%)5 (2%) 1.0 cm127 (100%)155 (66%) 2.0 cm0 (0%)75 (32%)Portal filed size (cm)^a^ Right-left (RL)10.8 ± 1.18.4 ± 1.2\<0.001 Superior-inferior (SI)10.2 ± 1.08.2 ± 1.0\<0.001 Anterior-posterior (AP)8.8 ± 0.97.7 ± 1.0\<0.001Grade 1--3 late gastrointesitinal toxicity rate (%)0.083 at 2 years3527 at 3 years3831 at 5 years4132Grade 2--3 late gastrointesitinal toxicity rate (%)\<0.001 at 2 years219 at 3 years239 at 5 years239Grade 1--3 late rectal bleeding rate (%)0.015 at 2 years3323 at 3 years3826 at 5 years3828Grade 2--3 late rectal bleeding rate (%)\<0.001 at 2 years217 at 3 years237 at 5 years237[^1][^2][^3]

Findings for toxicity are shown in Table [4](#RRS083TB4){ref-type="table"}. The maximum CTCAE Version 4.0 Grade toxicity was observed in the form of late genitourinary (GU) toxicity, late gastrointestinal (GI) toxicity including rectal bleeding, and late rectal bleeding alone. No Grade 4 or 5 late toxicity was observed; 5 patients (1%) suffered Grade 3 GU late toxicity and 10 (3%) Grade 3 GI late toxicity, all of which consisted of rectal bleeding; 14 patients (4%) suffered Grade 2 GU late toxicity and 35 (10%) Grade 2 late GI toxicity, 32 (9%) of which consisted of rectal bleeding. The actuarial 2-, 3-, and 5-year Grade 1--3 GU late toxicity rates were 13%, 17% and 23%, respectively, and the corresponding figures for Grade 2--3 were 2%, 4% and 6% (Fig. [2](#RRS083F2){ref-type="fig"}). The 2-, 3-, and 5-year Grade 1--3 GI late toxicity rates were 30%, 33% and 36%, respectively, and the corresponding figures for Grade 2--3 were 13%, 14% and 14% (Fig. [3](#RRS083F3){ref-type="fig"}). The 2-, 3-, and 5-year Grade 1--3 late rectal bleeding rates were 26%, 30% and 31%, respectively, and the corresponding figures for Grade 2--3 were 12%, 13% and 13%. Fig. 2.Grade 2--3 late genitourinary toxicity. The 2-, 3- and 5-year toxicity rates were 2%, 4% and 6%, respectively. Fig. 3.Grade 2--3 late gastrointestinal toxicity. The 2-, 3- and 5-year toxicity rates were 13%, 14% and 14%, respectively. Table 4.Grade of late toxicityLate genitourinary toxicityLate gastrointestinal toxicityLate rectal bleeding*n*%*n*%*n*%Grade 351103103Grade 21443510329Grade 1591679226618Grade 0281782356525169Missing313131Total362100362101362100[^4][^5]

When the patients were divided into a 2D- and a 3D-simulation group, the respective 2-, 3- and 5-year Grade 1--3 GI toxicity rates were 35%, 38% and 41% for 2D, and 27%, 31% and 32% for 3D (*P* = 0.083). The corresponding figures for Grade 2--3 were 21%, 23% and 23% for 2D, and 9%, 9% and 9% for 3D (*P* \< 0.001) (Table [3](#RRS083TB3){ref-type="table"}). Similarly, the respective 2-, 3- and 5-year Grade 1--3 rectal bleeding rates were 33%, 38% and 38% for 2D, and 23%, 26% and 28% for 3D (*P* = 0.015), and the corresponding figures for Grade 2--3 were 21%, 23% and 23% for 2D, and 7%, 7% and 7% for 3D (*P* \< 0.001) (Fig. [4](#RRS083F4){ref-type="fig"}). Fig. 4.Grade 2--3 late rectal bleeding. The 2-, 3- and 5-year occurrence rates were 21%, 23% and 23% for 2D simulation, and 7%, 7% and 7% for 3D simulation, respectively (*P* \< 0.001).

DISCUSSION {#s4}
==========

To describe and analyse late toxicity is of the utmost importance for the use of radiation therapy for the treatment of prostate cancer. A number of publications have dealt with late toxicity in prostate radiotherapy \[[@RRS083C2]--[@RRS083C13]\]. However, most of these studies examined mixed populations with respect to prescribed dose, dose fractionation, or beam arrangements (for example, number of beam ports and their gantry angles). Therefore, the quantity of pure data for the effect of portal field size on late toxicity has been insufficient.

In Japan, prostate cancer was not considered to be a commonly occurring cancer until around 2000. Moreover, radical prostatectomy was preferred to radiotherapy by most urologists until that time \[[@RRS083C14]\]. However, the rate of prostate cancer incidence has been rapidly increasing recently \[[@RRS083C15]\], and at the same time, definitive radiotherapy has become the prevailing treatment mode. For these reasons, quite a few institutions did not have much experience with definitive radiotherapy for prostate cancer around 2000, when the subjects of our study were treated (1998--2006). Five representative institutions in the Osaka area, where radiation oncologists who had been trained at Osaka University were employed, participated in this study. These oncologists principally followed the same procedure as the one used at Osaka University, that is, the classical 4-field technique using anterior--posterior and lateral beams with 70 Gy in 35 fractions regardless of T-stage, Gleason Score or pretreatment prostate-specific antigen level. In fact, we found that 378 of all 436 patients (87%) enrolled in the previous survey study of ours had been treated with the same dose-fractionation of 70 Gy in 35 fractions. In view of this finding, we decided to embark upon this second survey to investigate solely the relationship between portal field size and late toxicity for a uniform setting of dose and beam arrangements.

To the best of our knowledge, our study cohort is one of the largest series treated with a uniform dose-fractionation and irradiation technique (classical 4-field technique). Moreover, all the institutions changed their simulation method from simple X-ray film-based simulation (2D) to CT simulation (3D) by the end of data acquisition for this study, which enabled us to compare the field size of 3D and 2D simulation. The results were very clear and easy to understand: 3D simulation reduced the field size significantly, as well as the rate of GI late toxicity, especially rectal bleeding. The reason for this improvement is deemed to be simply that with the smaller irradiation field the rectum could be largely avoided. There might be a speculation that not only field sizes but also the width of the MLC made an impact on the toxicities. We analysed the influence of the width of the MLC, but no statistically significant impact was detected (data not shown), we think because the number of patients treated with other than 1 cm-width MLC was too small compared to the 1 cm-width group. This issue should be addressed with other cohorts in other studies.

A strength of this study may well be that the surveyors were all physicians: no non-physicians participated. Moreover, they were mostly the same physicians that had treated the patients who were the subject of this paper. This makes a high degree of accuracy likely for the data collection, although it should be noted that this study was of a retrospective nature. On the other hand, a variation was observed in the incidence rate of Grade 1 toxicity among the five institutions as follows; 14--33% for 5-year Grade 1 GU late toxicity, 17--36% for GI and 13--30% for rectal bleeding. This variation might indicate that the incidence rate of Grade 1 depended on and was influenced by the physicians who followed up patients, especially in a retrospective analysis; therefore, the significance of the figures presented as Grade 1 toxicity should be considered as relatively low.

The rate of Grade 2--3 late toxicity detected in our study was similar to, or slightly higher than, the findings of other studies in the literature. Dearnaley *et al.* \[[@RRS083C6]\] reported that, in their randomized controlled trial in which all patients were treated with 64 Gy, radiation-induced Grade 2 or higher proctitis and bleeding occurred in 5% in the conformal group compared to 15% in the conventional group (*P* = 0.01). They found no difference between groups in bladder function after treatment (20 vs. 23% for Grade 2 or more, *P* = 0.61). It should be noted, however, that the toxicity scales used for their study were the Radiation Therapy Oncology Group (RTOG) criteria \[[@RRS083C16]\]. Morris *et al*. \[[@RRS083C7]\] conducted an evidence-based review of 3-dimensional conformal radiotherapy (3D-CRT) as part of an American Society for Radiation Oncology (ASTRO) outcomes initiative. In the Task Force Conclusion, they stated that 3D-CRT reduces late morbidity, particularly GI late morbidity, with the dose to the rectum limited. No benefits in terms of GU symptoms or sexual function were observed. Their conclusion thus shows good agreement with ours. Zelefsky *et al*., in their reports of the long-term results for 3D-CRT \[[@RRS083C8]\] and intensity-modulated radiotherapy (IMRT) \[[@RRS083C9]\] noted that, with 3D-CRT, the 5-year actuarial likelihood of Grade 2 and 3 late GI toxicities was 11% and 0.75%, respectively, while the corresponding findings for GU were 10% and 3%. With IMRT, the 10-year actuarial likelihood of Grade 2 and 3 late GI toxicities was 2% and 1%, respectively, while the corresponding findings for GU were 11% and 5%. The shapes of their actuarial toxicity curves resembled those of ours. That is, the GI toxicity curve reached a plateau at 2 or 3 years after radiotherapy, while the GU toxicity curve gradually rose until 10 years or more after radiotherapy. However, none of these studies provided detailed information on portal field size or its relation to late toxicity.

Dearnaley *et al*. had addressed this issue by a prospective randomized trial comparing 1.0 and 1.5 cm margins, arriving at the conclusion that the larger margin had been associated with the significantly higher incidence of toxicities \[[@RRS083C2]\]. However, their study had included only 126 patients, who had been assigned to 2 × 2 arms (64 Gy and 74 Gy groups, and, 1.0 and 1.5 cm margin groups). Moreover, their treatment planning had included two phases comprising a 3-field (anterior and left/right lateral or posterior oblique fields) phase and a 6-field (left and right, anterior/posterior oblique and lateral fields) phase. Although those patients had been randomly assigned, such critical heterogeneity of the cohort in total dose (64 Gy and 74 Gy) and treatment planning approach (3-field and 6-field) might make the interpretation complicated in terms of reproducibility. We considered that our current study could still add information and complement the conclusion drawn by Dearnaley *et al.*, because it included a significantly larger number of patients (362 patients) and the treatment was in a more homogeneous manner (all with 70 Gy by 4-field) in spite of its weakness as a retrospective study.

The main criticism of our study might be that the kind of data on which it is based is so classical that no direct clinical indicators such as V~40Gy~ or V~65Gy~ of the rectum, could be provided as dose-volume constraints for modern 3D treatment planning for 3D-CRT or IMRT. However, the authors believe that the data presented here are still meaningful in terms of (i) describing a certain era of Japanese standard practice, (ii) providing radiation oncologists and treatment planners with a valuable reference because of the clear correspondence between a given portal field size (as a final block-to-block distance that would be relevant even for the most up-to-date irradiation technology) and a given rate of late toxicity, and (iii) providing suggestions for newly emerging irradiation technique in terms of a tolerance level that should not be exceeded, as detailed next.

CONCLUSION {#s5}
==========

In conclusion, we investigated late toxicity associated with EBRT for prostate cancer under conditions of a uniform setting of classical 4-field 70 Gy in 35 fractions. The use of CT simulation and the resultant reduction in the portal field size were significantly associated with diminished GI late toxicity, especially with less rectal bleeding. Typically, the field size was significantly reduced from 10.8 × 10.2 × 8.8 cm (2D simulation) to 8.4 × 8.2 × 7.7 cm (3D simulation), and at the same time, the rate of Grade 2--3 late rectal bleeding was significantly reduced from 23% to 7%. In view of the high overall and cause-specific survival rates observed in our study, any novel innovative radiotherapy should not exceed a late toxicity level of 7% for Grade 2--3 rectal bleeding in order to improve the quality of life of the patients or at least keep it the same as with "classical radiotherapy".
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[^1]: ^a^Mean ± standard deviation.

[^2]: Grade: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

[^3]: Late gastrointestinal toxicity included late rectal bleeding.

[^4]: Grade: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

[^5]: Late gastrointestinal toxicity included late rectal bleeding.
